CANbridge Pharmaceuticals Accelerates Drug Development
Company Announcements

CANbridge Pharmaceuticals Accelerates Drug Development

CANbridge Pharmaceuticals Inc. (HK:1228) has released an update.

CANbridge Pharmaceuticals Inc. reports significant headway in their drug pipeline for rare diseases, with the commercial launch of Hunterase® and Livmarli® in China and the progression of CAN103 through clinical trials. The company has also ventured into gene therapy, licensing a novel technology for Duchenne Muscular Dystrophy treatment, and expects to submit a New Drug Application for CAN103 by the end of 2024.

For further insights into HK:1228 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App